Last reviewed · How we verify

NCT07069660: COMPASS 3

Compass 3: A Novel Transition Program to Reduce Disability After Stroke

Recruiting now NA Last updated 13 February 2026
What this trial tests

NA trial testing COMPASS in Stroke in 520 participants. Currently enrolling.

Timeline
29 September 2025
Primary endpoint
31 March 2030
31 March 2030

Quick facts

Lead sponsorWashington University School of Medicine
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment520
Start date29 September 2025
Primary completion31 March 2030
Estimated completion31 March 2030
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Washington University School of Medicine

Who can join

55 and older, any sex, with Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates a program designed to help individuals transition from inpatient rehabilitation to home following an ischemic or hemorrhagic stroke. Half of the participants will receive a stroke education program while the other half will receive an environmental modifications program.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of COMPASS

Trials testing the same drug.

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other Washington University School of Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07069660.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing